Ginkgo Bioworks launched ADME-One, a fully integrated high-throughput ADME platform co-developed with Tangible Scientific and Inductive Bio, offering five Tier 1 assays and AI-driven human PK projections. The U.S.-based workflow delivers turnkey compound management and standardized data at a price several times lower than industry offshore alternatives.
On May 26, Ginkgo Bioworks announced the launch of ADME-One, a high-throughput ADME platform co-developed with Tangible Scientific and Inductive Bio. This integrated service offers automated Tier 1 ADME assays and AI-driven human pharmacokinetic projections within a single workflow.
ADME-One consolidates five Tier 1 assays—microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding—executed in Ginkgo’s automated Boston laboratory. Inductive Bio’s Compass platform translates these data into multiparameter human PK models while Tangible Scientific manages compound intake, plating, real-time tracking, and logistics.
The fully U.S.-based service undercuts traditional offshore costs by several times and returns results in days, enabling early hit identification and fewer synthesis cycles. Ginkgo strengthened its small molecule drug discovery team by hiring Jonathan Grob as Vice President of Small Molecules, reinforcing its AI-enabled platform with seasoned medicinal chemistry leadership.
